Drug intelligence / Profile preview

gentamicin + mupirocin

Development stage
Phase 4
Lead developer
GSK
Modality
Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
Administration
Topical
01

Overview

This is a topical combination of two antibiotics, gentamicin and mupirocin, formulated to treat bacterial skin infections. Gentamicin is an aminoglycoside antibiotic that binds to the 30S subunit of bacterial ribosomes, inhibiting protein synthesis and leading to cell death. It is effective against a broad range of gram-negative bacteria as well as some gram-positive organisms. Mupirocin is a polyketide antibiotic that inhibits bacterial protein synthesis by reversibly binding to bacterial isoleucyl-tRNA synthetase (isoleucine--tRNA ligase), thereby blocking the incorporation of isoleucine into proteins. This results in bacteriostatic or bactericidal activity depending on concentration and exposure time. The combination provides dual antibacterial action targeting both gram-positive (notably Staphylococcus aureus) and gram-negative pathogens, making it useful for mixed or resistant skin infections[2][3][7].

Other names
gentamicin and mupirocinmupirocin/gentamicin combination
02

Targets

Bacterial RibosomeIleRS (Isoleucyl-tRNA synthetase)

Beyond the preview

Go deeper on gentamicin + mupirocin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on gentamicin + mupirocin.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call